Spruce Biosciences, Inc. focuses on developing and commercializing novel therapies for rare endocrine disorders.The company is developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia.
